Sana reports Q2 2026 progress on SC451, SG293 as Mayo Clinic invests $25M

Sana Biotechnology reported second quarter 2026 results on August 10, 2026, detailing progress on two lead programs moving toward the clinic. For SC451, an iPSC-derived pancreatic islet cell therapy for type 1 diabetes, the company is conducting activities to prepare for an IND submission and Phase 1/2 trial start, including near-term completion of GLP toxicology studies and technology transfer to its contract manufacturer, and expects to file an IND and begin the trial as early as this year.¹

For SG293, a CD8-targeted fusosome designed to deliver genetic material for CD19-directed CAR T cells in non-Hodgkin lymphoma, Sana expects to generate first-in-human data as early as this year.¹ Preclinical data presented at the ASGCT 2026 Annual Meeting showed a SG293 surrogate achieved cell-specific delivery and deep B cell depletion in non-human primates without lymphodepleting chemotherapy.¹

On the diabetes franchise, Sana announced that the New England Journal of Medicine published a peer-reviewed letter titled "Long-Term Survival of Hypoimmune Allogeneic Islets without Immunosuppression," discussing 14-month results from an investigator-sponsored study of UP421.¹ Results through 14 months showed survival and function of transplanted pancreatic beta cells as measured by circulating C-peptide, with no safety issues identified and evasion of immune detection.¹ The company also announced a strategic collaboration with Mayo Clinic to advance SC451, under which Mayo Clinic made a $25.0 million equity investment.¹

For the preclinical BCMA-directed program SG227, Sana is preparing to begin clinical testing as early as mid-2027, contingent upon the early clinical profile of SG293.¹

On financing, cash, cash equivalents, and marketable securities as of June 30, 2026 were $160.5 million, up from $138.4 million at year-end 2025,¹ and the company said it expects cash runway into mid-2027.¹